Sam Altman, OpenAI co-founder and ChatGPT visionary, shares his personal journey with psychedelics, highlighting their impact on his mental health and his vision for their future in mental health care through his investment in Journey Colab. Journey Colab aims to bring psychedelic therapies like MDMA and psilocybin to market for conditions like depression, PTSD, and addiction, starting with luxury rehab centers but with a commitment to accessibility for marginalized communities.